Login to Your Account

Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial

By Donna Young

Tuesday, June 17, 2008
Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription